Silexion Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	2.41	5.99	1.19	4.6
Cash & Short-Term Investments	2.41	5.99	1.19	4.6
Cash Growth	-60.78%	404.72%	-74.17%	-
Other Current Assets	1.65	0.65	1.06	0.38
Total Current Assets	4.07	6.64	2.25	4.98
Net Property, Plant & Equipment	0.4	0.44	0.56	0.25
Other Long-Term Assets	0.13	0.14	0.05	0.03
Total Assets	4.6	7.22	2.86	5.26
Accounts Payable	1.76	1.7	1.72	0.32
Accrued Expenses	0.56	0.88	0.64	1.57
Short-Term Debt	1.55	-	1	-
Current Portion of Leases	0.19	0.18	0.16	0.11
Other Current Liabilities	-	-	0	0.2
Total Current Liabilities	4.06	2.76	3.52	2.2
Long-Term Debt	-	1.57	2.96	-
Long-Term Leases	0.25	0.29	0.37	0.06
Total Long-Term Liabilities	0.25	1.85	3.33	0.06
Total Liabilities	4.31	4.61	6.85	2.26
Common Stock	0.05	0.04	0	-
Additional Paid-in Capital	58.14	57.73	39.26	11.34
Retained Earnings	-57.9	-55.17	-43.25	-26.81
Shareholders' Equity	0.29	2.6	-3.99	-15.48
Total Liabilities & Equity	4.6	7.22	2.86	5.26
Total Debt	1.99	2.04	4.49	0.17
Net Cash (Debt)	0.42	3.96	-3.3	4.42
Net Cash Growth	-89.28%	-	-	-
Net Cash Per Share	2.10	29.75	-793.56	5939.50
Book Value	0.29	2.6	-3.99	-15.48
Book Value Per Share	1.44	19.58	-958.09	-20777.50
Tangible Book Value	0.29	2.6	-3.99	-15.48
Tangible Book Value Per Share	1.44	19.58	-958.09	-20777.50

SEC Filings: 10-K · 10-Q